Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 1

Healio

Patients on B-cell depleting therapies at risk for breakthrough COVID-19, severe outcomes -

Patients with immune-mediated inflammatory diseases receiving B-cell depleting therapies are at risk for COVID-19 regardless of vaccine status, but outpatient use of monoclonal antibodies

1553733214702804995

Healio Rheumatology

ICYMI: Patients with IMIDs receiving #Bcell depleting therapies are at risk of #COVID19 infection, regardless of vaccine status @ClevelandClinic https://t.co/UlLyTozoJh - view on twitter

More coverage: #BCell #covid19

Read the full article here

See more from Healio Rheumatology